The Medicines Company (NASDAQ: -MDCO) announced that the results of ESCAPE -2, a pivotal Phase 3 efficacy trial of its investigational agent Cleviprex™ (clevidipine butyrate) injectable emulsion, were published in the July

The study, published online in the Journal of Allergy and Clinical Immunology, calls for trials of aggressive therapies against childhood eczema in attempt to reduce the incidence of asthma in later life.
The study, conducted by the University of Melbourne, Monash University and Menzies Research Institute